A bullish thesis on Stryker Corporation emphasizes its entrenched position in healthcare, strong brand loyalty, and recurring procedure-driven demand. The medical technology company reported first-quarter 2026 net sales of $6.0 billion, up 2.6% year over year, with organic sales growth of 2.4% and adjusted earnings per share of $2.60. Management maintained full-year guidance of 8.5% organic sales growth and adjusted earnings per share of $14.90 to $15.10 despite a late-quarter cyber incident. Stryker pays an annual dividend of $3.52 per share, yielding 1.17% with a 40.74% payout ratio, and has increased its dividend for 16 consecutive years. The thesis points to the company's diversified portfolio across orthopedics, surgical equipment, and neurotechnology as a foundation for long-term earnings and cash flow compounding.
Stryker CorporationArticle highlights durable procedure-driven demand and strong brand loyalty for Stryker's medical devices.
Medtronic PLC